Aditxt, Inc. (NASDAQ:ADTX) Sees Significant Drop in Short Interest

Aditxt, Inc. (NASDAQ:ADTX) was the target of a large drop in short interest in September. As of September 15th, there was short interest totaling 51,400 shares, a drop of 60.9% from the August 31st total of 131,300 shares. Based on an average trading volume of 841,900 shares, the short-interest ratio is currently 0.1 days. Approximately 1.0% of the company’s stock are sold short. Approximately 1.0% of the company’s stock are sold short. Based on an average trading volume of 841,900 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Aditxt

An institutional investor recently raised its position in Aditxt stock. IFP Advisors Inc grew its holdings in shares of Aditxt, Inc. (NASDAQ:ADTX) by 66,926.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,054 shares of the company’s stock after purchasing an additional 10,039 shares during the quarter. IFP Advisors Inc owned approximately 17.64% of Aditxt worth $45,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.54% of the company’s stock.

Aditxt Stock Performance

Shares of NASDAQ:ADTX opened at $0.76 on Friday. The stock’s fifty day simple moving average is $1.02 and its two-hundred day simple moving average is $1.99. Aditxt has a 1-year low of $0.73 and a 1-year high of $775.00.

Aditxt (NASDAQ:ADTX) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($3.45) earnings per share for the quarter. Aditxt had a negative net margin of 206,431.38% and a negative return on equity of 316.98%.

About Aditxt

Aditxt, Inc, a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.